Presentation Title

Prevalence of Weight-Inducing Drug Use in Adults: NHANES 2013-2018

Presenter Credentials

Lizbeth Ramos, College of Pharmacy, third year, PharmD Gabriela Sastre-Perez, College of Pharmacy, third year, PharmD Abdallah Salman, College of Pharmacy, third year, PharmD

Presenter Degree

Degree in Progress

Co-Author Credentials

Lizbeth Ramos, College of Pharmacy, third year, PharmD Gabriela Sastre-Perez, College of Pharmacy, third year, PharmD Abdallah Salman, College of Pharmacy, third year, PharmD Alexandra Perez Rivera, PharmD, MS, College of Pharmacy Associate Professor

College

College of Pharmacy

Campus Location

Ft. Lauderdale

Format

Poster

IRB Approval Verification

Yes

Abstract

Objective The objectives of this study are to evaluate the use of weight-inducing drugs (WID) in the U.S., and determine trends in use among those at higher risk for cardiovascular disease.

Rationale Drugs known to cause a significant amount of weight gain are select insulins, antipsychotics, antidepressants, antiepileptics, antihyperglycemics, steroids, antihistamines, beta blockers, and all contraceptives including other hormone therapies. To our knowledge, there are no observational studies that have evaluated frequency, prevalence, or percentage of adults using WID. This is significant because weight gain can exacerbate the risk of cardiac morbidity and mortality.

Methods This observational cohort study used data from NHANES using 3 survey cycles(2013-2018). Included were adults 40 years and older who were not pregnant. Our outcome was defined as the use of select WID by their respective drug classes. Predictors evaluated were select sociodemographic and clinical predictors(number of chronic conditions(prior diagnoses hypertension, dyslipidemia, coronary artery disease, diabetes, or heart attack), body mass index, and waist circumference). Odds ratios with 95% confidence intervals quantified these associations. Analyses were adjusted for complex sampling survey design and estimates are nationally representative. IBM SPSS, version 27, was used for all analyses.

Results Our final cohort included 11,452 participants. Results showed 3,596(30.0%; 95% CI 28.6-31.4%) participants were on any WID. Use of these agents increased over time from 32.6% to 34%(p<0.05). Use was highest for beta blockers(12.5%) and lowest for prescription antihistamines(1%.). In unadjusted models, participants over 65 years of age, non-Hispanic whites, an education level of high school or lower, high risk waist circumference, female and a previous heart attack, were significantly more likely to be on a WID. The odds of being on a WID increased significantly with an increasing number of chronic conditions. Conclusion 30% of adults 40 years and older were on at least one WID and use significantly increased over time. Use of WID was most prevalent in subgroups with a higher risk of weight gain and cardiovascular morbidity and mortality. Future research should evaluate the impact of WID on long-term cardiovascular outcomes. IPE: N/A References: N/A

Selection Criteria

1

This document is currently not available here.

COinS
 

Prevalence of Weight-Inducing Drug Use in Adults: NHANES 2013-2018

Objective The objectives of this study are to evaluate the use of weight-inducing drugs (WID) in the U.S., and determine trends in use among those at higher risk for cardiovascular disease.

Rationale Drugs known to cause a significant amount of weight gain are select insulins, antipsychotics, antidepressants, antiepileptics, antihyperglycemics, steroids, antihistamines, beta blockers, and all contraceptives including other hormone therapies. To our knowledge, there are no observational studies that have evaluated frequency, prevalence, or percentage of adults using WID. This is significant because weight gain can exacerbate the risk of cardiac morbidity and mortality.

Methods This observational cohort study used data from NHANES using 3 survey cycles(2013-2018). Included were adults 40 years and older who were not pregnant. Our outcome was defined as the use of select WID by their respective drug classes. Predictors evaluated were select sociodemographic and clinical predictors(number of chronic conditions(prior diagnoses hypertension, dyslipidemia, coronary artery disease, diabetes, or heart attack), body mass index, and waist circumference). Odds ratios with 95% confidence intervals quantified these associations. Analyses were adjusted for complex sampling survey design and estimates are nationally representative. IBM SPSS, version 27, was used for all analyses.

Results Our final cohort included 11,452 participants. Results showed 3,596(30.0%; 95% CI 28.6-31.4%) participants were on any WID. Use of these agents increased over time from 32.6% to 34%(p<0.05). Use was highest for beta blockers(12.5%) and lowest for prescription antihistamines(1%.). In unadjusted models, participants over 65 years of age, non-Hispanic whites, an education level of high school or lower, high risk waist circumference, female and a previous heart attack, were significantly more likely to be on a WID. The odds of being on a WID increased significantly with an increasing number of chronic conditions. Conclusion 30% of adults 40 years and older were on at least one WID and use significantly increased over time. Use of WID was most prevalent in subgroups with a higher risk of weight gain and cardiovascular morbidity and mortality. Future research should evaluate the impact of WID on long-term cardiovascular outcomes. IPE: N/A References: N/A